tirzepatide shortage update today Update: On December 19th the FDA ruled the tirzepatide was resolved, however is giving a grace period for compounding pharmacies to continuing manufacturing. This grace period is 60 days. On FDA Announced Removal of Tirzepatide

Save on Tirzepatide treatment with Medicare Through the Medicare GLP-1 Bridge Program or our flat-rate compounded option, MDWatch delivers more clinical support than most national telehealth brands

Combining Tirzepatide with other weight loss medications or treatments may not be recommended, as it could increase the risk of side effects

Some report mild nausea for up to 810 weeks at higher doses

Assuming Eli Lilly follows a similar timeline to tirzepatide, the earliest possible FDA approval for retatrutide would likely occur in late 2027 or 2028, depending on Phase 3 trial results and regulatory review timelines

Every time you receive a new vial, read the label

Importantly, tirzepatide carries a boxed warning for risk of thyroid C-cell tumors and is contraindicated in patients with a personal or family history of medullary thyroid carcinoma or in patients with Multiple Endocrine Neoplasia syndrome type 2 (MEN2)